AIM: Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction and potentially progresses to fatal thrombosis. The 4Ts scoring system has been reported as a clinical pretest for HIT. However, its usefulness in critically ill patients has not yet been thoroughly examined. Thus, we evaluated the clinical usefulness of the 4Ts score in the diagnosis of HIT in critically ill patients. METHODS: One hundred and four critically ill patients who were admitted to our intensive care unit and who underwent the antiplatelet factor 4/heparin complex antibodies (PF4/heparin Ab) test with suspected HIT were enrolled in the study. The primary endpoint variable was the 4Ts score. The secondary endpoint variables were laboratory data, length of stay, and mortality, compared between thePF4/heparin Ab positive and negative groups. RESULTS: There was no significant difference in the 4Ts scores between the PF4/heparin Ab positive and negative groups. The positive predictive value (HIT patients/4T high score patients) was 15.4% (2/13), the negative predictive value (non-HIT patients/4T low score patients) was 87.5% (42/48), and the false-negative rate for the 4Ts score (4T low score patients/HIT patients) was as high as 54.5% (6/11). The PF4/heparin Ab positive patients had longer stay in intensive care compared to the PF4/heparin Ab negative patients (P = 0.035). CONCLUSIONS: The present study showed the discrepancy between the 4Ts score and PF4/heparin Ab. When HIT is suspected in critically ill patients, an immediate HIT antibody test and initiation of therapeutic management of HIT are required regardless of the 4Ts score.
AIM: Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction and potentially progresses to fatal thrombosis. The 4Ts scoring system has been reported as a clinical pretest for HIT. However, its usefulness in critically ill patients has not yet been thoroughly examined. Thus, we evaluated the clinical usefulness of the 4Ts score in the diagnosis of HIT in critically ill patients. METHODS: One hundred and four critically ill patients who were admitted to our intensive care unit and who underwent the antiplatelet factor 4/heparin complex antibodies (PF4/heparin Ab) test with suspected HIT were enrolled in the study. The primary endpoint variable was the 4Ts score. The secondary endpoint variables were laboratory data, length of stay, and mortality, compared between thePF4/heparin Ab positive and negative groups. RESULTS: There was no significant difference in the 4Ts scores between the PF4/heparin Ab positive and negative groups. The positive predictive value (HIT patients/4T high score patients) was 15.4% (2/13), the negative predictive value (non-HIT patients/4T low score patients) was 87.5% (42/48), and the false-negative rate for the 4Ts score (4T low score patients/HIT patients) was as high as 54.5% (6/11). The PF4/heparin Ab positive patients had longer stay in intensive care compared to the PF4/heparin Ab negative patients (P = 0.035). CONCLUSIONS: The present study showed the discrepancy between the 4Ts score and PF4/heparin Ab. When HIT is suspected in critically ill patients, an immediate HIT antibody test and initiation of therapeutic management of HIT are required regardless of the 4Ts score.
Authors: Mark Andrew Crowther; Deborah J Cook; Martin Albert; David Williamson; Maureen Meade; John Granton; Yoanna Skrobik; Stephan Langevin; Sangeeta Mehta; Paul Hebert; Gordon H Guyatt; William Geerts; Christian Rabbat; James Douketis; Nicole Zytaruk; Joanne Sheppard; Andreas Greinacher; Theodore E Warkentin Journal: J Crit Care Date: 2010-02-10 Impact factor: 3.425
Authors: Mark A Crowther; Deborah J Cook; Maureen O Meade; Lauren E Griffith; Gordon H Guyatt; Donald M Arnold; Christian G Rabbat; William H Geerts; Theodore E Warkentin Journal: J Crit Care Date: 2005-12 Impact factor: 3.425
Authors: Marc Carrier; Greg A Knoll; Michael J Kovacs; Jane C Moore; Dean Fergusson; Marc A Rodger Journal: Thromb Res Date: 2006-11-13 Impact factor: 3.944
Authors: C Pouplard; P Gueret; M Fouassier; C Ternisien; M Trossaert; S Régina; Y Gruel Journal: J Thromb Haemost Date: 2007-03-14 Impact factor: 5.824